Research Article

PET Evidence of the Effect of Donepezil on Cognitive Performance in an Animal Model of Chemobrain

Ilhan Lim,1,2 Hye-Young Joung,3 A Ram Yu,1 Insop Shim,3 and Jin Su Kim1

1Division of R1-Convergence Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea
2Department of Nuclear Medicine, Korea Cancer Center Hospital, Seoul 01812, Republic of Korea
3Department of Science in Korean Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea

Correspondence should be addressed to Insop Shim; ishim@khu.ac.kr and Jin Su Kim; jinsukim601@gmail.com

Received 25 March 2016; Accepted 30 June 2016

Academic Editor: Eng King Tan

Copyright © 2016 Ilhan Lim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A considerable number of patients with breast cancer complain of cognitive impairment after chemotherapy. In this study, we showed that donepezil enhanced memory function and increased brain glucose metabolism in a rat model of cognitive impairment after chemotherapy using behavioral analysis and positron emission tomography (PET). We found that chemotherapy affected spatial learning ability, reference memory, and working memory and that donepezil improved these cognitive impairments. According to PET analysis, chemotherapy reduced glucose metabolism in the medial prefrontal cortex and hippocampus, and donepezil increased glucose metabolism in the bilateral frontal lobe, parietal lobe, and hippocampus. Reduced glucose metabolism was more prominent after treatment with doxorubicin than cyclophosphamide. Our results demonstrated the neural mechanisms for cognitive impairment after chemotherapy and show that cognition was improved after donepezil intervention using both behavioral and imaging methods. Our results suggested that donepezil can be employed clinically for the treatment of cognitive deficits after chemotherapy.

1. Introduction

A considerable number of patients with breast cancer complain of cognitive impairment after chemotherapy. Cognitive deficits in such patients consist of hippocampus-dependent memory and executive functions associated with the frontal lobe. Similar cognitive impairment was also shown in animal models [1–3]. Chemotherapy-associated cognitive dysfunction was referred to as chemobrain. Selamat and colleagues reported that awareness of cognitive changes was dependent on the healthcare and cultural context. To overcome chemobrain, various interventions such as cognitive training, methylphenidate, and erythropoietin have been performed [4–8]. Chemobrain was also found when patients with B-cell non-Hodgkin lymphomas were given rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, vincristine and rituximab, or vincristine and bendamustine [9]. Chiaravalloti’s group reported that brain glucose metabolism in patients with Hodgkin disease was affected after diagnosis and during chemotherapy treatment [10]. Ponto’s group reported that breast cancer survivors treated with chemotherapy may manifest long-term changes in brain glucose metabolism indicative of subtle frontal hypometabolism [11]. Simó’s group reported a long-term decrease in gray matter and white matter volume in chemotherapy-treated patients [12].

Donepezil, a reversible acetylcholinesterase inhibitor, improves cognition for the patients with Alzheimer’s disease and stroke traumatic brain injury and even for normal older adults [13–16]. However, to the best of our knowledge, there was no report on the effect of donepezil to chemobrain. In the present study, we investigated the effect of donepezil on memory function and brain glucose metabolism in a rat chemobrain model using behavioral test and positron emission tomography (PET).
2. Materials and Methods

2.1. Animal and the Experimental Design. Female Sprague-Dawley rats weighting 250–280 g each were used. The animals were allowed to acclimatize themselves for at least 7 days prior to the experimentation. The animals were housed in individual cages under light-controlled conditions (12/12 h light/dark cycle) and at 25°C room temperature. Food and water were made available. This experimental protocol was approved by an Institutional Review Committee for the Use of Human or Animal Subjects or the procedures are in compliance with at least the Declaration of Helsinki for human subjects or the National Institutes of Health Guide for Care and Use of Laboratory Animals (Publication number 85-23, revised 1985), the UK Animals Scientific Procedures Act 1986, or the European Communities Council Directive of 24 November 1986 (86/609/EEC). The rats were allowed to adapt to their environment at least 1 week before the experiments.

Chemobrain rat model was constructed using doxorubicin or cyclophosphamide because doxorubicin or cyclophosphamide was widely used in chemotherapy. Trimethyltin chloride (C5H9ClSn) (TMT) was also used as a control of cognitive dysfunction group for the comparison with chemobrain model. TMT is a potent neurotoxicant that selectively induces neuronal death in both human and animal limbic system and in particular in the hippocampal formation.

Rats were divided into six groups of ten individuals as follows: normal control group (group 1, \( n = 10 \)), control group of cognitive dysfunction group induced by TMT (group 2, \( n = 10 \)), cyclophosphamide-treated group (group 3, \( n = 10 \)), doxorubicin-treated group (group 4, \( n = 10 \)), cyclophosphamide-treated and donepezil administered group (group 5, \( n = 10 \)), and doxorubicin-treated and donepezil administered group (group 6, \( n = 10 \)). To generate a rat model of chemotherapy, 100 mg/kg of cyclophosphamide was intraperitoneally (IP) injected for groups 3 and 4. 4 mg/kg of doxorubicin was IP injected for groups 4 and 6 once a week for 3 weeks. For donepezil intervention groups, 5 mg/kg of donepezil was IP administrated every day for 3 weeks. 8 mg/kg of TMT was injected to induce cognitive dysfunction group for group 2.

2.2. Behavioral Study. The Morris water maze test was performed to evaluate spatial learning ability and reference memory [17]. The swimming pool of the Morris water maze was a circular water tank 200 cm in diameter and 35 cm deep. It was filled to a depth of 21 cm with water at 23°C. A platform 15 cm in diameter and 20 cm in height was placed inside the tank with its top surface being 1.5 cm below the surface of the water. The pool was surrounded by many cues that were external to the maze. A CCD camera was equipped with a personal computer for the behavioral analysis. Each rat received four daily trials. For 4 consecutive days, the rats were tested with three acquisition tests. They also received retention tests on the 5th day. For the acquisition test, the rat was allowed to search for the hidden platform for 180 s and the latency to escape onto the platform was recorded. The animals were trained to find the platform that was in a fixed position for 4 days for the acquisition test, and then, for the retention test (at the 5th day), they received a 1 min probe trial in which the platform was removed from the pool. The intertrial interval time was 1 min. The performance of the test animals in each water maze trial was assessed by a personal computer for the behavioral analysis (S-mart program, Spain). Passive avoidance test was also performed to assess explicit memory function [18].

2.3. FDG PET. Siemens Inveon PET was used in this study. Regional cerebral glucose metabolism in the same groups of rats was measured using F-18 fluorodeoxyglucose (FDG) PET after behavioral test. The FDG PET scan was performed to assess cerebral glucose metabolism for chemobrain and the effect of donepezil interventions compared to normal control. Before PET scanning, the rats were fasted for at least 8 h, after they were anesthetized with 2% isoflurane in 100% oxygen (Forane Solution; Choong Wae Pharma, Seoul, South Korea). During PET scanning, the temperature of rats was kept at 36°C with heating pads. Heart rates were monitored using a BioVet system (M2M Imaging Corp., USA). After injection of FDG (18.5 MBq/100 g body weight), 40 min of emission PET data was acquired. Transmission PET data were acquired for 15 min after emission PET scan. Emission list-mode data were sorted into 3D sinograms and reconstructed using 3D reprojection (3DRP) algorithms. No filter was applied. The image matrix was 256 × 256 × 159, the pixel size 0.155 × 0.155 mm², and the slice thickness 0.796 mm.

Voxel-wise statistical analysis was performed to identify the regional differences between groups using SPM 8 (http://www.fil.ion.ucl.ac.uk/spm/). For SPM analysis, the brain region of interest was extracted and a study-specific rat brain template was constructed. Individual PET data were spatially normalized onto the rat brain template. Spatial normalization for individual PET was performed using affine and non-linear transformations. The voxel size of spatially normalized images was 0.3 × 0.3 × 0.3 mm³, 3 mm of Gaussian smoothing kernel was applied for enhancing the signal to noise ratio. Count normalization was also performed. Two sample t-tests were used to identify regional differences between groups with a threshold of \( P < 0.05 \) (uncorrected).

3. Results

Figures 1(a) and 1(b) show the result of the Morris water maze test after administration of each chemotherapeutic agent, chemobrain rats needed more time to acquire information, and memory retention was impaired. After donepezil intervention these impairments were partially rescued, indicating that while chemotherapeutic agents affected spatial learning ability and reference memory, donepezil facilitated their recovery.

Figures 1(c) and 1(d) show the result of the passive avoidance test. The result shows that response times decreased after administration of each chemotherapeutic agent, and cerebral glucose metabolism was partially recovered after administration of donepezil for both the doxorubicin and cyclophosphamide induced chemobrain. This suggests that explicit working memory was impaired after chemotherapy.
treatment; however, donepezil intervention could improve the cognitive function. Recovery of cognitive function after administration of donepezil was more evident for doxorubicin induced chemobrain group compared to cyclophosphamide induced chemobrain group.

Figure 2(a) and Supplementary Figure 1a, in Supplementary Material available online at http://dx.doi.org/10.1155/2016/6945415, show the result of decrease of cerebral glucose metabolism after chemotherapy with cyclophosphamide in the region of bilateral medial prefrontal cortices ($P < 0.05$).

Figure 2(b) and Supplementary Figure 1b show that the result of cerebral glucose metabolism was decreased in the region of left medial prefrontal cortex and bilateral hippocampus after doxorubicin chemotherapy when compared with the normal untreated group ($P < 0.05$).

Figure 2(c) and Supplementary Figure 1c show the increase of glucose metabolism in the region of the bilateral medial prefrontal cortices, bilateral hippocampi ($L > R$), bilateral medial hippocampi, and bilateral parietal cortices after intervention with donepezil for cyclophosphamide-treated group ($P < 0.05$).

Figures 2(d) and 1(d) show the increase of glucose metabolism in the region of bilateral global area of the cortices including the bilateral frontal, bilateral parietal, bilateral temporal, and bilateral hippocampi in the doxorubicin-treated group after donepezil intervention ($P < 0.05$).

Histochemical analysis demonstrated that the number of neurons in the hippocampus and the expression of choline acetyltransferase in the hippocampus decreased after each chemotherapeutic treatment, and donepezil intervention expedited the restoration of these, although these differences were not statistically significant (Supplementary Figure 2).

4. Discussion

More than half (up to 75%) of the patients with cancer complain of cognitive impairment during or after treatment of their cancer. Breast cancer survivors in particular suffer
Figure 2: Continued.
BioMed Research International

Figure 2: Brain regions showing decreased (blue) or increased (red) FDG brain uptake. T-map was overlaid on the rat brain template. Decrease in brain glucose metabolism after chemotherapy at a threshold of $P < 0.05$, uncorrected (a) in the bilateral medial prefrontal cortices for the cyclophosphamide-treated group and (b) in the left medial prefrontal cortex and bilateral hippocampi for the doxorubicin-treated group compared to normal control. Increase of brain glucose metabolism after donepezil intervention at a threshold of $P < 0.05$, uncorrected (c) in the bilateral medial prefrontal cortices, bilateral hippocampi ($L > R$), bilateral medial hippocampi, and bilateral parietal cortices for the cyclophosphamide-treated group and (d) in the bilateral global area of the cortices including the frontal, parietal, and temporal cortices and bilateral hippocampi for the doxorubicin-treated group, when compared with the respective chemotherapy-treated groups without donepezil intervention.

from such impairment because survival after breast cancer is prolonged compared with other cancers. Longitudinal studies and meta-analyses have revealed evidence for chemotherapy-induced cognitive deficits in a subgroup of patients with breast cancer [1, 19]. The cognitive impairment ranged over diverse domains of cognition including working memory, executive function, attention, and processing speed [2]. A number of studies have used animal models of chemotherapy to understand the mechanisms underlying these cognitive changes. Cognitive impairment in patients with cancer after chemotherapy was considered significant with the increase of the survival rates of patients after cancer treatment.

Donepezil was widely used for the improvement of cognition in clinics for Alzheimer's disease, stroke, traumatic brain injury, and normal older adults. Donepezil is a reversible acetylcholinesterase inhibitor, which can facilitate the synaptic supply of acetylcholine, enhance cholinergic neural pathways, and consequently improve cognitive function [13, 14, 16, 20, 21].

In this present study, behavioral analysis revealed that chemotherapy affected spatial learning ability, reference memory, and working memory and that donepezil improved these cognitive impairments. According to PET results, chemotherapy reduced glucose metabolism in the medial prefrontal cortex and hippocampus, and donepezil increased glucose metabolism in the bilateral frontal cortices, parietal cortices, and hippocampus. Decreased glucose metabolism was more prominent after doxorubicin treatment than cyclophosphamide treatment.

In comparison with glucose metabolism change in patients after chemotherapy, results of the present study correlate with those of earlier study in that glucose metabolism decreased in the region of prefrontal cortex for rat model and glucose metabolism decreased in the region of bilateral orbitofrontal cortex in patients. It requires caution to interpret these findings because there might be significant difference between species and different chemotherapy regimens [10].

Our results revealed cognitive improvement after donepezil intervention using both behavioral and imaging methods. This suggests that donepezil could be used in clinics for the treatment of cognitive deficits after chemotherapy. The cerebral glucose metabolic responses after donepezil intervention in the present study correspond with those reported by previous studies. Using MRI, these studies reported increased activation in the bilateral prefrontal areas, inferior frontal lobes, and the left inferior parietal lobe after donepezil administration to patients with stroke [22]. They also reported selective increases of brain glucose metabolism after donepezil treatment in patients with Alzheimer's disease [23] and increased brain glucose metabolism after donepezil administration to rhesus monkeys [24].

Our results demonstrate that chemotherapy impairs cognitive function and brain glucose metabolism and that donepezil enhances these features in a rat model of chemotherapy. The present results concur with those of earlier studies, in which cyclophosphamide and/or doxorubicin affected passive avoidance learning, novel object recognition, and memory retention [25, 26], although other studies have reported no impairment after cyclophosphamide [27] or doxorubicin [28] administration. With respect to the changes in brain metabolism and structure after chemotherapy, we previously reported decreased brain glucose metabolism in the temporal lobe and cingulate gyrus after chemotherapy in patients with breast cancer [29]. Other studies have reported cerebral white matter changes [30] in the frontal
and temporal lobes; gray matter changes [31] in the frontal and temporal lobes, cerebellum, and thalamus; and gray and white matter changes [32] in the prefrontal cortex, parahippocampal gyrus, and precuneus after chemotherapy. The mechanism of cognitive improvement after donepezil intervention is thought to involve modulation of cognitive function by restoring the shortage of intracerebral cholinergic neurotransmitters through inhibition of acetylcholine hydrolysis [33]. Acetylcholine plays a role as a modulator of the cortex in task-related cerebral plasticity and is essential for learning, memory, language, and attention [14, 22]. The result in our present study was well in accordance with those of a recent study [34] that reported a reduction in cognitive impairment after donepezil intervention in a mouse chemotherapy model; however, they employed a different chemotherapeutic regimen and their study was confined to behavioral examination.

The result in this present study collectively shows the effect of donepezil in a rat chemobrain model using behavioral and imaging analysis at the same time.

5. Conclusion
Our results suggest that donepezil may improve cognitive function and brain glucose metabolism after cognitive impairment in a rat chemotherapy model. Further clinical investigation is warranted to administer donepezil for cognitive deficits after chemotherapy.

Disclosure
The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the paper. Hye-Young Joung’s current address is Asan Institute for Life Sciences, Asan Medical Center.

Competing Interests
The authors declare that there are no competing interests regarding the publication of this paper.

Authors’ Contributions
Ilhan Lim and Hye-Young Joung are co-first authors and equally contributed to this work.

Acknowledgments
This work was supported by grants from HO15C0003 (PI: Jin Su Kim) and NRF-2012M2A2A7013480 (PI: Joo Hyun Kang) of the Korea Science and Engineering Foundation funded by the Ministry of Education, Science and Technology.

References
[1] K.-A. Phillips and J. Bernhard, “Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions,” Journal of the National Cancer Institute, vol. 95, no. 3, pp. 190–197, 2003.
[2] T. A. Ahles and A. J. Saykin, “Candidate mechanisms for chemotherapy-induced cognitive changes,” Nature Reviews Cancer, vol. 7, no. 3, pp. 192–201, 2007.
[3] R. Seigers and J. E. Fardell, “Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research,” Neuroscience and Biobehavioral Reviews, vol. 35, no. 3, pp. 729–741, 2011.
[4] R. J. Ferguson, T. A. Ahles, A. J. Saykin et al., “Cognitive-behavioral management of chemotherapy-related cognitive change,” Psycho-Oncology, vol. 16, no. 8, pp. 772–777, 2007.
[5] H. G. Mar Fan, M. Clemons, W. Xu et al., “A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer,” Supportive Care in Cancer, vol. 16, no. 6, pp. 577–583, 2008.
[6] J. A. O'Shaughnessy, S. J. Vukelja, F. A. Holmes et al., “Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy,” Clinical Breast Cancer, vol. 5, no. 6, pp. 439–446, 2005.
[7] H. C. F. Moore, “An overview of chemotherapy-related cognitive dysfunction, or chemobrain,” Oncology, vol. 28, no. 9, pp. 797–804, 2014.
[8] M. H. Selamat, S. Y. Loh, L. Mackenzie, and J. Vardy, “Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications,” PLoS ONE, vol. 9, no. 9, Article ID e108002, 2014.
[9] P. Zimmer, A. Mierau, W. Bloch et al., “Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine,” Leukemia and Lymphoma, vol. 56, no. 2, pp. 347–352, 2015.
[10] A. Chiavaravalli, M. Pagani, M. Cantonetti et al., “Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: an 18F-FDG PET/CT study,” Oncology Letters, vol. 9, no. 2, pp. 685–690, 2015.
[11] L. L. B. Ponto, Y. Menda, V. A. Magnotta, T. H. Yamada, N. L. Denburg, and S. K. Schultz, “Frontal hypometabolism in elderly breast cancer survivors determined by [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study,” International Journal of Geriatric Psychiatry, vol. 30, no. 6, pp. 587–594, 2015.
[12] M. Simó, X. Rifà-Ros, A. Rodriguez-Fornells, and J. Bruna, “Chemobrain: a systematic review of structural and functional neuroimaging studies,” Neuroscience and Biobehavioral Reviews, vol. 37, no. 8, pp. 1311–1321, 2013.
[13] L. Zhang, R. C. Plotkin, G. Wang, M. E. Sandel, and S. Lee, “Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury,” Archives of Physical Medicine and Rehabilitation, vol. 85, no. 7, pp. 1050–1055, 2004.
[14] M. L. Berthier, J. Hinojosa, M. D. C. Martín, and I. Fernández, “Open-label study of donepezil in chronic poststroke aphasia,” Neurology, vol. 60, no. 7, pp. 1218–1219, 2003.
[15] S. E. Black, R. Doody, H. Li et al., “Donepezil preserves cognition and global function in patients with severe Alzheimer disease,” Neurology, vol. 69, no. 5, pp. 459–469, 2007.
[16] J. A. Yesavage, M. S. Mumenthaler, J. L. Taylor et al., “Donepezil and flight simulator performance: effects on retention of complex skills,” Neurology, vol. 59, no. 1, pp. 123–125, 2002.

[17] R. G. M. Morris, P. Garrud, J. N. P. Rawlins, and J. O’Keefe, “Place navigation impaired in rats with hippocampal lesions,” Nature, vol. 297, no. 5868, pp. 681–683, 1982.

[18] R. Bartus, C. Flicker, and R. Dean, Eds., Logical Principles for the Development of Animal Models of Age-Related Memory Impairments, Mark Powley, New Canaan, Conn, USA, 1983.

[19] M. C. Janelsins, S. Kohli, S. G. Mohile, K. Usuki, T. A. Ahles, and G. R. Morrow, “An update on cancer- and chemotherapy-related cognitive dysfunction: current status,” Seminars in Oncology, vol. 38, no. 3, pp. 431–438, 2011.

[20] R. S. Doody, D. S. Geldmacher, B. Gordon, C. A. Perdomo, and R. D. Pratt, “Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease,” Archives of Neurology, vol. 58, no. 3, pp. 427–433, 2001.

[21] B. Winblad, K. Engedal, H. Soininen et al., “A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD,” Neurology, vol. 57, no. 3, pp. 489–495, 2001.

[22] W. H. Chang, Y. H. Park, S. H. Ohn, C.-H. Park, P. K. W. Lee, and Y.-H. Kim, “Neural correlates of donepezil-induced cognitive improvement in patients with right hemisphere stroke: a pilot study,” Neuropsychological Rehabilitation, vol. 21, no. 4, pp. 502–514, 2011.

[23] S. J. Teipel, A. Drzezga, P. Bartenstein, H.-J. Möller, M. Schwaiger, and H. Hampel, “Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer’s disease: A double-blind cross-over trial,” Psychopharmacology, vol. 187, no. 1, pp. 86–94, 2006.

[24] M. Asai, A. Fujikawa, A. Noda, S. Miyoshi, N. Matsuoka, and S. Nishimura, “Donepezil- and scopolamine-induced rCMRglu changes assessed by PET in conscious rhesus monkeys,” Annals of Nuclear Medicine, vol. 23, no. 10, pp. 877–882, 2009.

[25] J. E. MacLeod, J. A. DeLeo, W. F. Hickey, T. A. Ahles, A. J. Saykin, and D. J. Bucci, “Cancer chemotherapy impairs contextual but not cue-specific fear memory,” Behavioural Brain Research, vol. 181, no. 1, pp. 168–172, 2007.

[26] A. B. Reiriz, G. K. Reolon, T. Preissler et al., “Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice,” Clinical Cancer Research, vol. 12, no. 16, pp. 5000–5001, 2006.

[27] G. D. Lee, D. L. Longo, Y. Wang et al., “Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy,” Clinical Cancer Research, vol. 12, no. 1, pp. 198–205, 2006.

[28] M. Sieklucka-Dziuba, J. Saczonek, J. Dziuba, and Z. Kleinrok, “Central action of some cytostatics—methotrexate (MTX) and doxorubicin (DXR). II. The influence on the seizure activity and the learning and memory processes in mice,” Annales Universitatis Mariae Curie-Sklodowska D: Medicina, vol. 53, pp. 81–88, 1998.

[29] I. Lim, Y. K. Kim, H. S. Park et al., “The cerebral metabolic changes following neoadjuvant chemotherapy in breast cancer patients,” Journal of Nuclear Medicine, vol. 50, supplement 2, article 1275, 2009.

[30] S. Deprez, F. Amant, R. Yigit et al., “Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients,” Human Brain Mapping, vol. 32, no. 3, pp. 480–493, 2011.